ReviewExpert review of vaccines2008
Viral sequence diversity: challenges for AIDS vaccine designs.
Review in Expert review of vaccines, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 61 citations in OpenAlex.
- Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches.BMC infectious diseases · 2024Article
- Article
- Generation and characterization of infectious molecular clones of transmitted/founder HIV-1 subtype C viruses.Virology · 2023Article
- Employing computational tools to design a multi-epitope vaccine targeting human immunodeficiency virus-1 (HIV-1).BMC genomics · 2023Article
- Review
- V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers.Vaccines · 2019Review
- Analysis of viral diversity for vaccine target discovery.BMC medical genomics · 2017Article
- Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061).PloS one · 2016Article
- New prospects for a preventive HIV-1 vaccine.Journal of virus eradication · 2015Article
- A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.AIDS research and human retroviruses · 2014Article
- Article
- The Antibody Germline/Maturation Hypothesis, Elicitation of Broadly Neutralizing Antibodies Against HIV-1 and Cord Blood IgM Repertoires.Frontiers in immunology · 2014Article
- HIV-1 vaccines: challenges and new perspectives.Human vaccines & immunotherapeutics · 2014Review
- Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.Virology journal · 2013Article
- Dissecting the dynamics of HIV-1 protein sequence diversity.PloS one · 2013Article
- Article
- Use of a high resolution melting assay to analyze HIV diversity in HIV-infected Ugandan children.The Pediatric infectious disease journal · 2012Article
- Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine.AIDS research and human retroviruses · 2012Article
- Article
- The evolution of HIV: inferences using phylogenetics.Molecular phylogenetics and evolution · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Among the greatest challenges facing AIDS vaccine development is the intrinsic diversity among circulating populations of HIV-1 in various geographical locations and the need to develop vaccines that can elicit enduring protective immunity to variant HIV-1 strains. While variation is observed in all of the viral proteins, the greatest diversity is localized to the viral envelope glycoproteins, evidently reflecting the predominant role of these proteins in eliciting host immune recognition and responses that result in progressive evolution of the envelope proteins during persistent infection. Interestingly, while envelope glycoprotein variation is widely assumed to be a major obstacle to AIDS vaccine development, there is very little experimental data in animal or human lentivirus systems addressing this critical issue. In this review, the state of vaccine development to address envelope diversity will be presented, focusing on the use of centralized and polyvalent sequence design as mechanisms to elicit broadly reactive immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.